Anzeige
Mehr »
Login
Samstag, 19.10.2024 Börsentäglich über 12.000 News von 675 internationalen Medien
Diese Aktie steigt um 225%! Ist ein Kupfer-Engpass im Gange?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1W7NS | ISIN: FR0011466069 | Ticker-Symbol: E0J
Frankfurt
18.10.24
09:27 Uhr
4,010 Euro
-0,010
-0,25 %
Branche
Elektrotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
EKINOPS SAS Chart 1 Jahr
5-Tage-Chart
EKINOPS SAS 5-Tage-Chart
RealtimeGeldBriefZeit
3,9904,14013:04
PR Newswire
8 Leser
Artikel bewerten:
(0)

Ekinops Revenue up +9% in Q3 2024

PARIS, Oct. 15, 2024/PRNewswire/ -- EKINOPS (Euronext Paris - FR0011466069 - EKI), a leading supplier of telecommunications solutions for telecom operators and enterprises, reports its Q3 2024 consolidated revenue (July 1 to September 30, 2024).

€m - IFRS
Non-audited data

2023

2024

Change

Q1 revenue

31.9

28.3

-11 %

Q2 revenue

39.2

29.2

-25 %

Q3 revenue

27.8

30.4

+9 %

9-month revenue

98.8

87.9

-11 %

Q3 2024 revenue up +9% to €30.4m

In Q3 2024, Ekinops reported revenue of 30.4 m€, up +9% year-on-year and up +4% sequentially relative to Q2 2024. Ekinops thus returns to growth, posting its highest level of revenue since Q2 2023.

At constant exchange rates, Q3 2024 revenue increased by +10%.

For the first nine months of 2024, consolidated revenue was 87.9 m€, down -11% compared to the same period last year (identical at constant exchange rates).

Access up +8%, Optical Transport down -34% over nine months

Sales for Access solutions were up +8% over the period, driven by the significant rebound in business in France since the start of the year (+27% over nine months) with operators gradually rebuilding their equipment inventories.

Nine-month sales of Optical Transport solutions were down -34% year-on-year. In addition to an unfavorable basis for comparison (+23% over nine months in 2023), operators are still reluctant to start making investments in a context of overcapacity with a slowdown in internet traffic growth. However, Optical Transport sales grew +16% on a sequential basis compared to Q2 2024.

As of end-September 2024, Software & Services' revenue represented 16% of the Group's total revenue (vs. 15% a year earlier) with an increasing share of recurring revenue, particularly in Services.

+18% activity growth in France, -26% internationally

The first nine months of the year were characterized by Ekinops' strong performance in France , with robust growth of +18% over the period, propelled by the rebound in sales of Access solutions, the company's main business line in its home market. Over the period, the Group reported 45% of its total business volume in this region, versus 34% a year earlier.

Outside France, Ekinops saw a decline in its activities, which now account for 55% of its total revenue (vs. 66% a year earlier).

In North America , where sales are almost exclusively generated by Optical Transport solutions, the Group posted business volumes of 17.8 m€, down -29% versus the same period last year (-28% in US dollars), which represents a high comparison base (+18% growth at end-September 2023). The US market remains marked by a significant wait-and-see attitude adopted by service providers, linked to the slow deployment of the 42 billion dollars federal BEAD program (Broadband Equity, Access and Deployment), aimed at reducing the digital divide in the United States. Ekinops generated 20% of its revenue in this market in the first nine months of 2024 (vs. 26% one year prior).

The EMEA region (Europe, excluding France, the Middle East and Africa), representing 33% of Ekinops' revenue (vs. 39% a year earlier), recorded a -23% decline in business over the period, mainly penalized by a significant decrease in sales of Optical Transport solutions, on the back of a +17% increase over the same period last year. However, it should be noted that on a sequential basis, Ekinops saw a return to growth in this region during Q3 2024 (+9%).

As of end-September 2024, revenue for Asia-Pacific , which remains reliant on just a few key accounts, was down -31%. Over nine months, the region accounted for 2% of Ekinops' total revenue (identical to the prior year).

Outlook

In Q3 2024, Ekinops reported an improved level of revenue versus previous quarters, slightly over 30 m€, particularly thanks to Access inventory easing at operator-customers in France and EMEA, as well as the very first deliveries of the new 800G product for Optical Transport.

However, the market environment is still difficult, with operators across all regions notably cautious about their investment plans.

One of the company's objectives for 2024 - to achieve quarter-on-quarter growth - has been fulfilled, as the company added approximately 1 m€ in revenue in each quarter between Q1 and Q3.

2024 financial calendar

Date

Release

January 13, 2025

FY 2024 revenue

March 5, 2025

2024 annual results

All press releases are published after Euronext Paris market close.

EKINOPS Contact
Didier Brédy, Chairman and CEO
[email protected]

Investors
Mathieu Omnes, Investor relation
Tel.: +33 (0)1 53 67 36 92
[email protected]

Press
Amaury Dugast, Press relation
Tel.: +33 (0)1 53 67 36 74
[email protected]

Photo - https://mma.prnewswire.com/media/2531186/ekinops_corporate.jpg
Logo - https://mma.prnewswire.com/media/814911/Ekinops_Logo.jpg

SOURCE Ekinops

© 2024 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.